Resolution Bioscience to participate at the FDA-AACR Liquid Biopsy Workshop

USA Profile Username: jon@newsinnovations.com / edit profile Resolution Bioscience to participate at the FDA-AACR Liquid Biopsy Workshop PR Newswire SEATTLE, July 14, 2016 SEATTLE, July 14, 2016 /PRNewswire/ -- Resolution Bioscience is pleased to announce its participation in the upcoming FDA-AACR Liquid Biopsies in Oncology Drug and Device Development Workshop on July 19th, 2016.   The purpose of this workshop is to provide a forum for the discussion of relevant scientific advances in the field of liquid biopsies and of the regulatory environment that will support the translation of this emerging technology into improved patient care. The analysis of tumor-derived cell-free DNA (cfDNA) in plasma, a noninvasive method for detecting genetic alterations in tumors, holds considerable promise both for improving cancer diagnoses and monitoring and in drug development. Dr. Tera Eerkes, VP of Strategy and Clinical Operations, will present during the day's third Session, "Liquid Biopsy Test Development" and participate in the following panel discussion.  Topics will include the analytical performance of new diagnostics, use of contrived specimens for controls and performance testing, and tissue-to-plasma concordance. "We are enthused by the efforts of the FDA and AACR to seek input on the critical and unresolved questions of assessment and regulation of novel precision medicine technologies like Resolution Bioscience's ctDx™ platform," said Dr. Eerkes.  "As a leading NGS technology development company, we value the opportunity to include our expertise in the evolving conversation." The company develops custom cfDNA gene panels for pharmaceutical companies and research partners. The ctDx platform is currently being developed into a distributable kit, enabling access to this leading technology for CROs, reference labs, and research institutions. The ctDx platform was the first to demonstrate de novo fusion detection in cfDNA and is also able to detect SNVs, indels, and copy number alterations. Recent data was presented at ASCO, highlighting the ability to detect ALK fusions and resistance mutations in a longitudinal manner. Resolution Bioscience (Bellevue, WA) was founded in 2012 by leading experts in next generation sequencing, genomic analysis and commercial product development.  The company's mission is to transform cancer outcomes by providing physicians and pharmaceutical companies with clinic-ready, noninvasive diagnostic tools to guide the development and clinical implementation of personalized treatment strategies. info@resolutionbio.com www.resolutionbio.com   SOURCE Resolution Bioscience CONTACT: info@resolutionbio.com | 425.453.5020 Web Site: http://www.resolutionbio.com Follow Us To change the settings for your profile(s) or email delivery, go to https://prnmedia.prnewswire.com/profile/?action=editProfile and select the profile you would like to edit. You can select the industries, subjects, languages, geographical areas, companies, delivery options and delivery frequencies of your choice. In addition to current press releases, you can also find archived news, corporate information, photos, tradeshow news and much more on the PR Newswire for Journalists website: https://prnmedia.prnewswire.com To contact us, email: mediasite@prnewswire.com Please do not reply to this email; this is an automatically generated message. Copyright © PR Newswire Association LLC. All Rights Reserved. A UBM plc company. Our mailing address is: 350 Hudson Street, Suite 300 New York, NY 10014-4504